Photo caption (from left to right):
Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li, Chairman and CEO, WuXi AppTec; Dr. Beh Swan Gin, Permanent Secretary (Development), Ministry of Trade and Industry; Mr. Alvin Tan, Assistant Chief Executive Officer for Industry Cluster Group, JTC Corporation
SINGAPORE, May 23, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore. This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations.
The new 50-acre Singapore site is located in the thriving Tuas Biomedical Park with the master planning and development by JTC to encompass a total of seven plants at its full capacity, providing active pharmaceutical ingredient (API) R&D and manufacturing services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates. Embracing industry-leading green chemistry technology initiatives, this new site is dedicated to improving industrial practices and promoting sustainable development of the local community. As a key part of the company’s global network, the Singapore site will integrate closely with WuXi AppTec’s existing sites across Asia, Europe, and North America, offering effective CRDMO solutions for new drug R&D from discovery to commercialization with expanded flexibility and scalability.
Mr. Png Cheong Boon, Chairman of the Singapore Economic Development Board (EDB), said, “WuXi AppTec’s comprehensive CRDMO facility marks the company’s first foray into Singapore, and is a timely addition to Singapore’s thriving and growing pharmaceutical and biotechnology sector. With R&D and manufacturing activities housed under one roof, WuXi AppTec will be building a sizeable local team to drive the development of innovative therapeutics in Singapore to serve patients globally. Singapore remains committed to working with global healthcare partners to bring novel healthcare solutions to the rest of the world.”
“We are thrilled to break ground on our long-planned site in Singapore. The progress we’ve made with many of our local partners is remarkable,” said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. “As we continue to enhance our capabilities and capacities to deliver high-quality solutions that meet the evolving needs of our customers, the new Singapore site will help us better serve our customers both locally and around the world.”
“At WuXi AppTec, our vision is that one day every drug can be made and every disease can be treated,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “We are proud to work with like-minded partners in Singapore to carry out this vision for the global pharmaceutical and life sciences industry. With the enhanced capacity and capabilities we are building at this new Singapore site, we look forward to continuing to help our customers accelerate the development and commercialization of life-saving treatments and medicines for patients around the world.”
The new Singapore site is projected to start operation in 2027 and will be built in different phases. The site is expected to bring approximately 1,600 employment opportunities once fully built.
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
Media Contact:
Davy Wu
mediainquiries@wuxiapptec.com
